SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus

Abstract

Background: Laboratory diagnosis of SARS-CoV-2 infection (the cause of COVID-19) uses PCR to detect viral RNA (vRNA) in respiratory samples. SARS-CoV-2 RNA has also been detected in other sample types, but there is limited understanding of the clinical or laboratory significance of its detection in blood. Methods: We undertook a systematic literature review to assimilate the evidence for the frequency of vRNA in blood, and to identify associated clinical characteristics. We performed RT-PCR in serum samples from a UK clinical cohort of acute and convalescent COVID-19 cases (n=212), together with convalescent plasma samples collected by NHS Blood and Transplant (NHSBT) (n=462 additional samples). To determine whether PCR-positive blood samples could pose an infection risk, we attempted virus isolation from a subset of RNA-positive samples. Results: We identified 28 relevant studies, reporting SARS-CoV-2 RNA in 0-76% of blood samples; pooled estimate 10% (95%CI 5-18%). Among serum samples from our clinical cohort, 27/212 (12.7%) had SARS-CoV-2 RNA detected by RT-PCR. RNA detection occurred in samples up to day 20 post symptom onset, and was associated with more severe disease (multivariable odds ratio 7.5). Across all samples collected ≥28 days post symptom onset, 0/494 (0%, 95%CI 0-0.7%) had vRNA detected. Among our PCR-positive samples, cycle threshold (ct) values were high (range 33.5-44.8), suggesting low vRNA copy numbers. PCR-positive sera inoculated into cell culture did not produce any cytopathic effect or yield an increase in detectable SARS-CoV-2 RNA. Conclusions: vRNA was detectable at low viral loads in a minority of serum samples collected in acute infection, but was not associated with infectious SARS-CoV-2 (within the limitations of the assays used). This work helps to inform biosafety precautions for handling blood products from patients with current or previous COVID-19.

Quantitative assessment of SARS‐CoV‐2 RNAemia and outcome in patients with coronavirus disease 2019

“…The search identified 2837 publications, and 21 studies involving 2182 patients were finally included 5,21‐40 (Figure 1). A retrospective study design was used in the majority of included studies (17/21).…”

The Effects of COVID-19 on Placenta and Pregnancy: What Do We Know So Far?

“…Arguably, the mere detection of viral RNA in the blood/serum does not reflect infectivity of a virus. Andersson et al (2020) found that all their reverse transcription-polymerase chain reaction (RT-PCR)-positive clinical samples show neither viral replication nor display any cytopathic effect after inoculation in cell culture [ 64 ]. More studies are warranted to resolve these uncertainties.…”

A tricompartmental model of lung oxygenation disruption to explain pulmonary and systemic pathology in severe COVID-19

“…In our proposed model, severe COVID-19 alveolitis is intimately associated with a lung vasculopathy, with extrapulmonary effects potentially stemming from the unique way in which the virus interferes with the physiology of the tricompartmental model. Generally, SARS-CoV-2 RNA is not detectable in the blood in milder infection, but can be detected in some severe cases [49][50][51][52] and correlates with interleukin-6 concentrations in critically ill patients. 53 Patients with detectable RNA in the blood were found to be older and to have more comorbidities, and were more likely to require ICU admission and mechanical ventilation.…”